

RECEIVED
OCT 25 2000

RECEIVED
OCT 25 2000

TECH CENTER 1600/2800

TECH CENTER 1600/2800

Subst. Form PTO-1449 APPLICANT'S(S') INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 25795-4-2	Serial No.: 09/419,517
	Applicant(s): KAESEMEYER	
	Filing Date: October 18, 1999	Group: 1614

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
<i>Z</i>	FA	5,273,875	12/1993	Griffith	435	1	
<i>Z</i>	FB	5,366,738	11/1994	Rork et al.	424	473	
<i>jm</i>	FC	5,767,160	6/1998	Kaesemeyer	574	565	
<i>jm</i>	FD	5,968,983	10/1999	Kaesemeyer	514	564	

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
<i>jm</i>	FE	WO 99/18952	22.04.99	International	—	—	

OTHER ART

<i>No copies</i>	FF	Duggan, D.E. et al. <u>The Physiological Disposition of Lovastatin</u> . Drug Metabolism and Disposition, Vol. 17, No. 2. pp. 166-173. 1989.
<i>jm</i>	FG	Morris et al. An Integrated Approach to the Selection of Optimal Salt from a New Drug Candidate, International Journal of Pharmaceutic (Amsterdam), 105(3), 209-217, 1994, see abstract.
<i>No copies</i>	FH	Vickers, S. et al. <u>Metabolic Disposition Studies on Simvastatin, a Cholesterol-Lowering Prodrug</u> . Drug Metabolism and Disposition, Vol. 18, No. 2. pp. 135-145. 1990.

Examiner:	Date Considered: 4/30/00
-----------	--------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 25795-4-2	SER. NO. 09/419,517
	APPLICANT KAESEMEYER	
	FILING DATE October 18, 1999	GROUP ART UNIT 1614

OCT 20 2000
 PATENT & TRADEMARK OFFICE

RECEIVED

OTHER DOCUMENTS
 (Including Author, Title, Date, Relevant Pages, Place of Publication)

OCT 25 2000

Examiner Initial			TECH CENTER 1601/2900
	EA	Haman, M. et al. <u>Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury.</u> Circulation, Vol. 90. No. 3, pp. 1357-1362. September, 1994.	
	EB	Harrison, D.G. <u>Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis.</u> J. Am. Coll. Cardiol. Vol. 17. pp. 71B-6B. 1991.	
	EC	Cooke, J.P. et al. <u>Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta.</u> Circulation. Vol. 83. pp. 1057-1062. 1991.	
	ED	Witzum, J.L. et al. <u>Role of Oxidized Low Density Lipoprotein in Atherogenesis.</u> J. Clin. Invest. Vol. 88. pp. 1785-1792. 1991.	
	EE	Mugge, A.J. et al. <u>Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits.</u> Circ. Res. Vol. 69. pp. 1293-1300. 1991.	
	EF	Forstermann, U. et al. <u>Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries.</u> Circ. Res. Vol. 62. pp. 185-191. 1988.	
	EG	Cohen, R.A. et al. <u>Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia.</u> Circ. Res. Vol. 63. pp. 903-910. 1988.	
	EH	Schwarzacher, A.P. et al. <u>Local Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty.</u> Circulation, Vol. 95. No. 7. pp. 1863-1869. April 1, 1997.	
	EI	Verbeuren, T.J. et al. <u>Effect of Hypercholesterolemia on Vascular Reactivity in the Rabbit. I: Endothelium-Dependent and Independent Contractions and Relaxations in Isolated Arteries of Control and Hypercholesterolemic Rabbits.</u> Circ. Res. Vol. 58. pp. 552-564. 1986.	
			DATE CONSIDERED
			11/30/00

No Copies

25795-4-2

09/419,517

RECEIVED

OCT 25 2000

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER

FILING DATE

October 18, 1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
<i>[Signature]</i>	5,543,430	Aug. 6, 1996	Kaesemeyer	514/565	
<i>[Signature]</i>	5,428,070	Jun. 27, 1995	Cooke et al.	514/557	
<i>[Signature]</i>	5,316,765	May 31, 1994	Folkers et al.	424/94.1	
<i>[Signature]</i>	5,196,195	Mar. 23, 1993	Griffith	424/94.6	
<i>[Signature]</i>	5,158,883	Oct. 27, 1992	Griffith	435/240.2	
<i>[Signature]</i>	5,132,453	Jul. 21, 1992	Griffith	562/560	
<i>[Signature]</i>	5,059,712	Oct. 22, 1991	Griffith	562/560	
<i>[Signature]</i>	4,686,211	Aug. 11, 1987	Hara et al.	514/418	

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
<i>[Signature]</i>	AA	Patel, J. M. et al. <u>Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells</u> . (Abstract Only) Free Radical Biology & Medicine. Vol. 20, No. 5. pp. 629. 1996.
<i>[Signature]</i>	AB	Xia, Y. et al. <u>Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury</u> . Proc. Natl. Acad. Sci. USA. Vol. 93. pp. 6770-6774. June 1996.
<i>[Signature]</i>	AC	Jeremy, R. W. et al. <u>Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit</u> . Circulation. Vol. 94, No. 3. pp. 498-506. August 1, 1996.
<i>[Signature]</i>	AD	Block, E. R. et al. <u>Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells</u> . (Abstract Only) Am. J. Physiol. Vol. 269. L574-L580. 1995.
<i>[Signature]</i>	AE	Mayer, B. et al. <u>Brain Nitric Oxide Synthase is a Biopterin-and Flavin-Containing Multi-Functional Oxido-Reductase</u> . (Abstract Only) FEBS 10045. Vol. 288, No. 1,2. pp. 187-191. August 1991.
<i>[Signature]</i>	AF	Weidinger, F. F. et al. <u>Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery</u> . Circulation. Vol. 81, No. 5. pp. 1667-1679. May 1990.
		DATE CONSIDERED
		11/30/00

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not consider
Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

25795-4-2

SER. NO.

09/419,517

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER


FILING DATE

October 18, 1999

GROUP ART UNIT

1614

(37 CFR 1.98(b))



RECEIVED

OTHER DOCUMENTS

OCT 25 2000

(Including Author, Title, Date, Relevant Pages, Place of Publication)

TECH CENTER 1600/2900

Examiner Initial		
	BA	Chester, A. H. et al. <u>Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries</u> . The Lancet. Vol. 336. pp. 897-900. Oct. 13, 1990.
	BB	Albina, J. E. et al. <u>Arginine Metabolism in Wounds</u> . Am. J. Physiol. Vol. 254. pp. E459-E467. 1988.
	BC	Cooke, J.P. et al. <u>Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit</u> . (Abstract Only) J. Clin. Invest. Vol. 90, No. 3. pp. 1168-72. Sep. 1992.
	BD	Nakamura, Y. et al. <u>Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study)</u> . (Abstract Only). Cardiovasc. Drugs. Ther., Vol. 10, No. 4, pp. 475-483. 1996.
	BE	Pohl, U. et al. <u>Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells</u> . (Abstract only) Atherosclerosis. Vol. 117. pp. 169-178. 1995.
	BF	Deliconstantinos, G. et al. <u>Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes</u> . (Abstract Only) Biochem. Pharm. Vol. 49. No. 11. pp. 1589-1600. 1995.
	BG	Galle, J. et al. <u>Effect of HDL and Atherogenic Lipoproteins on Formation of O₂ and Renin Release in Juxtaglomerular Cells</u> . (Abstract Only) Kidney International. Vol. 51. pp. 253-260. 1997.
	BH	Bult, H. <u>Nitric Oxide and Atherosclerosis: Possible Implications for Therapy</u> . (Abstract only) Molecular Medicine Today. p. 510. December 1996.
	BI	Crouse III, J.R. et al. <u>Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)</u> . (Abstract only) Am. J. Cardiol. Vol. 75. pp. 455-459. 1995.
	BJ	Aji, W. et al. <u>L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice</u> . (Abstract only) Circulation. Vol. 95. pp. 430-437. 1997.
	BK	Cooke, J. P. et al. <u>Arginine: A new Therapy for Atherosclerosis?</u> Circulation. Vol. 95. pp. 311-12. 1997.
	BL	Boger, R. H. et al. <u>The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications</u> . (First page only) Atherosclerosis. Vol. 127. pp. 1-11. 1996.
		DATE CONSIDERED
		11/30/00

EXAMINER: Initial citation consid r d. Draw lin through citation if not in conformance and not considere
Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

25795-4--2

SER. NO.

09/419,517

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

RECEIVED

OCT 25 1999

APPLICANT

KAESEMEYER

FILING DATE

October 18, 1999


GROUP ART UNIT

1614

(37 CFR 1.98(b))

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
	CA	Jay, M.T. et al. <u>Modulation of Vascular Tone By Low Density Lipoproteins/ Effects on L-Arginine Transport and Nitric Oxide Synthesis</u> . Experimental Physiology. Vol. 82. pp. 349-360. 1997.
	CB	Muramatsu, J. et al. <u>Hemodynamic Changes Associated with Reduction in Total Cholesterol By Treatment with the HMG-CoA Reductase Inhibitor Pravastatin</u> . Atherosclerosis. Vol. 130. pp. 179-182. 1997.
	CC	Sacks, F. M. et al. <u>The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels</u> . The New England Journal of Medicine. Vol. 335. pp. 1001-1009. October 3, 1996.
	CD	Bovan, A. J. van. et al. <u>Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris</u> . Circulation. Vol. 94. pp. 1503-1505. 1996.
no copies	CE	Lacoste, L. et al. <u>Comparative Effect of Pravastatin and Simvastatin on Platelet-Thrombus Formation in Hypercholesterolemic Coronary Patients</u> . JACC. Vol. 27 No. 2 Supp A. p. 413A. 1996.
	CF	Pitt, B. et al. <u>Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events</u> . J. Am. Coll. Cardiol. Vol. 26. pp. 1133-9. 1995.
	CG	Candipan, R.C. et al. <u>Regression or Progression: Dependency on Vascular Nitric Oxide</u> . Arterioscler. Thromb. Vas. Biol. Vol. 16. pp. 44-50. 1996.
	CH	Byington, R.P. et al. <u>Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program</u> . Circulation. Vol. 92. pp. 2419-2425. 1995.
	CI	Pritchard, K.A. et al. <u>Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion</u> . Circ. Res. Vol. 77 No. 3. pp. 510-518. 1995.
	CJ	Boger, R.H. et al. <u>Supplementation of Hypercholesterolemic Rabbits with L-Arginine Reduces the Vascular Release of Superoxide Anions and Restores NO Production</u> . Artherosclerosis. Vol. 117 No. 2. pp. 273-284. 1995.
		DATE CONSIDERED
		11/30/00

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(37 CFR 1.98(b))

APPLICANT

KAESEMEYER


FILING DATE

October 18, 1999

GROUP ART UNIT

1614

RECEIVED



OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

OCT 25 2000

TECH CENTER 1600/2300

Examiner Initial		
DA		Lacoste, L. et al. <u>Correction of the Increased Thrombogenic Potential with Cholesterol Reduction</u> . Circulation. Vol 92. pp. 3172-3177. 1995.
DB		Shepard, J. <u>Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia</u> . The New England Journal of Medicine Vol. 333. pp. 1301-1307. November 16, 1995.
DC		Philis-Tsimikas, A. et al. <u>L-Arginine May Inhibit Atherosclerosis Through Inhibition of LDL Oxidation</u> . Circulation. Vol. 92 (Supp. I). pp. I-422. 1995.
DD		Von der Leyen, H.E. et al. <u>Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene</u> . Proc. Natl. Acad. Sci. USA. Vol. 92. pp. 1137-1141. 1995.
DE		Egashira, K. et al. <u>Reduction in Serum Cholesterol with Pravastatin Improves Endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia</u> . Circulation. Vol. 89. pp. 2519-2524. 1994.
DF		Tsao, P. et al. <u>Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine</u> . Circulation. Vol. 89. pp. 2176-2182. 1994.
DG		Cayatte, A.J. et al. <u>Chronic Inhibition of Nitric Oxide Production Accelerates Neointima Formation and Impairs Endothelial Function in Hypercholesterolemic Rabbits</u> . Arterioscler. Thomb. Vol. 14. pp. 753-759. 1994.
DH		Wilcox, J.N. et al. <u>Expression of Multiple Nitric Oxide Synthase Isoforms in Human Aortic Fatty Streaks and Advanced Atherosclerotic Plaques</u> . (Abstract only) Circulation. Vol. 90 (Supp. I). pp. I-298. 1994.
DI		Chen, L. Y. et al. <u>Oxidated LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function</u> . Circulation. Vol. 93. pp. 1740-1746. 1993.
DJ		Wada, H. et al. <u>Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin</u> . Clin. Therap. Vol. 14. pp. 829-34. 1992.
DK		Dresler, H. et al. <u>Correction of Endothelial Dysfunction in Coronary Microcirculation of Hypercholesterolaemia Patients by L-Arginine</u> . The Lancet. Vol. 338. pp. 1546-1550. Dec. 21/28, 1991.

No Copies

DATE
CONSIDERED

11/30/00